Loading…
Emcure Pharmaceuticals (EMCURE)₹2,216−2.80%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Emcure Pharmaceuticals reported sales of ₹2,574 Cr, up 22.8% from Jun 2025, and net profit of ₹292 Cr, up 35.8% year on year. For the year to Mar 2026, sales were ₹9,187 Cr and net profit ₹940 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,660 | 1,665 | 1,768 | 1,812 | 1,998 | 1,959 | 2,112 | 2,097 | 2,266 | 2,357 | 2,466 | 2,574 |
| Expenses | 1,338 | 1,378 | 1,464 | 1,484 | 1,625 | 1,613 | 1,718 | 1,688 | 1,798 | 1,876 | 1,994 | 2,055 |
| Operating Profit | 328 | 293 | 310 | 335 | 380 | 354 | 401 | 416 | 474 | 492 | 479 | 531 |
| OPM % | 20.1% | 18.1% | 18.1% | 19.1% | 19.1% | 18.1% | 19.1% | 20.1% | 21.1% | 21.1% | 19.1% | 21.1% |
| Other Income | −1.99 | 21.99 | 11.99 | 22.98 | 35.96 | 3.99 | −5.99 | 0.00 | 2.99 | −35.98 | 13.99 | 1.99 |
| Interest | 59.15 | 61.11 | 65.17 | 59.17 | 46.13 | 32.08 | 39.10 | 27.08 | 33.11 | 38.12 | 46.09 | 32.09 |
| Depreciation | 70.02 | 84.01 | 90.90 | 93.91 | 97.04 | 96.97 | 97.01 | 98.96 | 105 | 105 | 106 | 110 |
| Profit before tax | 198 | 171 | 167 | 206 | 272 | 230 | 260 | 290 | 340 | 313 | 340 | 393 |
| Tax % | 26.0% | 30.0% | 27.0% | 26.0% | 26.0% | 32.0% | 24.0% | 26.0% | 26.0% | 26.0% | 29.0% | 26.0% |
| Exceptional items | −2.01 | −4.01 | 0.00 | 0.00 | 0.00 | 0.00 | −7.01 | −2.01 | 0.00 | −26.06 | 7.02 | 0.00 |
| Net Profit | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| EPS (Rs) | 7.70 | 6.28 | 6.37 | 7.96 | 10.30 | 8.12 | 9.98 | 10.94 | 12.86 | 12.17 | 12.86 | 15.52 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,705 | 5,039 | 5,018 | 5,845 | 5,973 | 6,646 | 7,879 | 9,187 | 9,663 |
| Expenses | 3,982 | 4,351 | 3,828 | 4,539 | 4,817 | 5,444 | 6,442 | 7,355 | 7,724 |
| Operating Profit | 747 | 706 | 1,213 | 1,326 | 1,180 | 1,226 | 1,466 | 1,860 | 1,976 |
| OPM % | 16.1% | 14.1% | 24.1% | 23.1% | 20.1% | 18.1% | 19.1% | 20.1% | 20.5% |
| Other Income | 71.99 | −25.01 | −159 | 62.98 | 38.95 | 46.99 | 61.98 | −18.99 | −17.01 |
| Interest | 224 | 258 | 155 | 177 | 215 | 238 | 176 | 144 | 149 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 384 | 415 | 426 |
| Profit before tax | 330 | 105 | 650 | 971 | 745 | 725 | 969 | 1,284 | 1,386 |
| Tax % | 37.0% | 4.0% | 36.0% | 28.0% | 25.0% | 27.0% | 27.0% | 27.0% | — |
| Exceptional items | −8.02 | −75.12 | −3.01 | 0.00 | −5.01 | −5.01 | −3.01 | −22.07 | −19.04 |
| Net Profit | 209 | 101 | 418 | 702 | 562 | 527 | 706 | 940 | 1,017 |
| EPS (Rs) | 10.81 | 4.63 | 23.16 | 36.68 | 29.43 | 27.52 | 35.99 | 48.85 | 53.41 |
| Dividend payout % | 32.1% | 54.1% | 4.0% | 8.1% | 7.0% | 7.0% | 8.1% | 7.1% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 | 190 |
| Reserves | 1,648 | 1,725 | 2,084 | 1,801 | 2,310 | 2,762 | 4,240 | 4,744 |
| Borrowings | 2,129 | 2,331 | 2,312 | 2,218 | 2,332 | 2,336 | 1,026 | 1,559 |
| Other Liabilities | 1,605 | 1,713 | 2,174 | 1,807 | 1,789 | 2,410 | 2,650 | 3,089 |
| Total Liabilities | 5,564 | 5,950 | 6,751 | 6,006 | 6,613 | 7,689 | 8,105 | 9,581 |
| Fixed Assets | 2,244 | 2,381 | 2,185 | 2,042 | 2,145 | 3,123 | 3,195 | 3,414 |
| CWIP | 582 | 486 | 302 | 321 | 412 | 159 | 177 | 172 |
| Investments | 0.00 | 0.00 | 0.00 | 24.92 | 24.90 | 317 | 94.62 | 19.91 |
| Other Assets | 2,738 | 3,083 | 4,263 | 3,619 | 4,031 | 4,091 | 4,637 | 5,976 |
| Inventories | 1,126 | 1,171 | 1,512 | 1,448 | 1,381 | 1,523 | 1,929 | 2,393 |
| Trade receivables | 973 | 1,144 | 1,476 | 1,310 | 1,649 | 1,860 | 2,001 | 2,563 |
| Cash & equivalents | 104 | 163 | 522 | 312 | 456 | 231 | 164 | 147 |
| Total Assets | 5,564 | 5,950 | 6,751 | 6,006 | 6,613 | 7,689 | 8,105 | 9,581 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 444 | 500 | 705 | 769 | 749 | 1,099 | 853 | 946 |
| Cash from investing activity | −410 | −168 | −257 | −576 | −469 | −717 | −96.32 | −1,196 |
| Cash from financing activity | −735 | −301 | −189 | −152 | −145 | −164 | −814 | 343 |
| Net cash flow | −702 | 32.10 | 260 | 42.13 | 134 | 220 | −58.14 | 94.24 |
| Capex | 416 | 155 | 146 | 421 | 402 | 307 | 406 | 547 |
| Free cash flow | 39.04 | 362 | 572 | 349 | 345 | 801 | 475 | 400 |
| CFO / OP % | 77.1% | 84.1% | 74.1% | 81.1% | 80.1% | 107.1% | 75.1% | 70.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 75 | 83 | 107 | 82 | 101 | 102 | 93 | 102 |
| Inventory days | 235 | 212 | 294 | 238 | 224 | 226 | 225 | 240 |
| Days payable | 142 | 133 | 188 | 184 | 175 | 193 | 172 | 177 |
| Cash conversion cycle | 167 | 161 | 212 | 135 | 148 | 134 | 145 | 164 |
| Working capital days | −15 | −28 | −16 | 9 | 22 | 28 | 76 | 62 |
| ROCE % | — | 11.0% | 22.0% | 26.0% | 21.0% | 19.0% | 21.0% | 24.0% |
For the Jun 2026 quarter, Emcure Pharmaceuticals reported sales of ₹2,574 Cr, up 22.8% year on year and net profit of ₹292 Cr, up 35.8% year on year. The operating margin was 21.1%.
Emcure Pharmaceuticals' sales for the year to Mar 2026 were ₹9,187 Cr; over the last twelve months they were ₹9,663 Cr.
Net profit for the year to Mar 2026 was ₹940 Cr, and ₹1,017 Cr over the last twelve months. Earnings per share over the same trailing period were ₹53.41.
Emcure Pharmaceuticals reported borrowings of ₹1,559 Cr at Mar 2026, against cash and equivalents of ₹147 Cr.
Cash from operations was ₹946 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹400 Cr.